The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Opsynvi, a once-daily tablet that includes both macitentan and tadalafil, to treat adults ...

Please provide your email address to receive an email when new articles are posted on . Nerandomilast is the first oral preferential phosphodiesterase 4B inhibitor approved for progressive pulmonary ...

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function. 1, 2 Affecting up to 100,000 people in the U.S. and up to 5.6 ...

A phlegmy cough and shortness of breath are possible warning signs of chronic obstructive pulmonary disease (COPD). Keeping track of your symptoms and knowing your risk factors can help you test ...

/PRNewswire/ -- Boehringer Ingelheim's JASCAYD® (nerandomilast) tablets has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of progressive pulmonary fibrosis (PPF) in ...

“Progressive pulmonary fibrosis is linked to underlying clinical ILD diagnoses including autoimmune ILDs – which can be caused by disorders like rheumatoid arthritis or systemic sclerosis – as well as ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.